Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.

Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway.
复制标题

丹参酮 IIA 通过 mTOR/p70S6K/RPS6/4E-BP1 信号通路抑制乳腺癌细胞中 HIF-1α 和 VEGF 的表达

DOI:
10.1371/journal.pone.0117440
复制
发表时间:
2015
期刊:
影响因子:
3.7
通讯作者:
Gao N
Gao N
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Li G;Shan C;Liu L;Zhou T;Zhou J;Hu X;Chen Y;Cui H;Gao N

文献摘要

参考文献

被引文献

相似文献

缺氧诱导因子1α(HIF-1α)和血管内皮生长因子(VEGF)在血管生成和肿瘤生长中起重要作用。丹参酮IIA(T2 A)是一种新型抗血管生成药物,具有良好的抗肿瘤作用,但其抗血管生成的分子机制尚不清楚。在本研究中,我们提供的证据表明,T2 A抑制血管生成和乳腺癌的生长通过下调VEGF的表达。T2 A在翻译水平抑制HIF-1α的表达,并抑制HIF-1α的转录活性,从而导致VEGF表达下调。T2 A对HIF-1α合成的抑制与哺乳动物雷帕霉素靶蛋白(mTOR)及其效应子核糖体蛋白S6激酶(p70 S6 K)和真核起始因子4 E结合蛋白1(4 E-BP 1)的强烈去磷酸化相关,4 E-BP 1是一种在翻译水平调节HIF-1α表达的途径。此外,我们还发现T2 A通过抑制HIF-1α和VEGF的表达,抑制人乳腺癌裸鼠移植瘤的血管生成和生长。我们的研究为人类乳腺癌的治疗提供了新的视角和潜在的靶点。
Hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF) play important roles in angiogenesis and tumor growth. Tanshinone IIA (T2A) is a novel antiangiogenic agent with promising antitumor effects; however, the molecular mechanism underlying the antiangiogenic effects of T2A remains unclear. In the present study, we provided evidence showing that T2A inhibited angiogenesis and breast cancer growth by down-regulating VEGF expression. Specifically, T2A repressed HIF-1α expression at the translational level and inhibited the transcriptional activity of HIF-1α, which led to the down-regulation of VEGF expression. Suppression of HIF-1α synthesis by T2A correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), a pathway regulating HIF-1α expression at the translational level. In addition, we also found that T2A inhibited the angiogenesis and growth of human breast cancer xenografts in nude mice through suppression of HIF-1α and VEGF. Our study provides novel perspectives and potential targets for the treatment of human breast cancer.
DOI: 10.1371/journal.pone.0033656
发表时间: 2012
期刊: PloS one
影响因子: 3.7
作者:
Gong Y;Li Y;Abdolmaleky HM;Li L;Zhou JR
通讯作者: Zhou JR
DOI: 10.1038/bcj.2013.7
发表时间: 2013-04-12
影响因子: 12.8
作者:
Li, G.;Zhou, T.;Liu, L.;Chen, J.;Zhao, Z.;Peng, Y.;Li, P.;Gao, N.
通讯作者: Gao, N.
DOI: 10.1158/1535-7163.mct-12-0180
发表时间: 2012-10
影响因子: 5.7
作者:
Chen CT;Du Y;Yamaguchi H;Hsu JM;Kuo HP;Hortobagyi GN;Hung MC
通讯作者: Hung MC
DOI: 10.1074/jbc.m512546200
发表时间: 2006-04-21
影响因子: 4.8
作者:
Chakraborty, G;Rangaswami, H;Kundu, GC
通讯作者: Kundu, GC
DOI: 10.1016/s1535-6108(03)00077-1
发表时间: 2003-04-01
期刊: CANCER CELL
影响因子: 50.3
作者:
Mabjeesh, NJ;Escuin, D;Giannakakou, P
通讯作者: Giannakakou, P